In　coronavirus　disease　2019　(COVID-19)　patients,　interleukin　(IL)-6　is　one　of　the　leading　factors　causing　death　through　cytokine　release　syndrome.　Hence,　identification　of　IL-6　downstream　from　clinical　patients＇　transcriptome　is　very　valid　for　analyses　of　its　mechanism.　However,　clinical　study　is　conditional　and　time　consuming　to　collect　optional　size　of　samples,　as　patients　have　the　clinical　heterogeneity.　A　possible　solution　is　to　deeply　mine　the　relative　existing　data.　Several　transcriptome-based　studies　on　other　diseases　or　treatments　have　revealed　different　genes　to　be　regulated　by　IL-6.　Through　our　meta-analysis　of　these　transcriptome　datasets,　352　genes　were　suggested　to　be　regulated　by　IL-6　in　different　biological　conditions,　some　of　which　were　related　to　virus　infection　and　cardiovascular　disease.　Among　them,　232　genes　were　not　identified　by　current　transcriptome　studies　from　clinical　research.　ICAM1　and　PFKFB3　were　the　most　significantly　upregulated　genes　in　our　meta-analysis　and　could　be　employed　as　biomarkers　in　patients　with　severe　COVID-19.　In　general,　a　meta-analysis　of　transcriptome　datasets　could　be　an　alternative　way　to　analyze　the　immune　response　and　complications　of　patients　suffering　from　severe　COVID-19　and　other　emergency　diseases.　(C)　2021　The　Authors.　Published　by　Elsevier　B.V.　on　behalf　of　Research　Network　of　Computational　and　Structural　Biotechnology.